Overview of Humalog KwikPen Mix 25
Humalog KwikPen Mix 25 by Lilly is a biphasic insulin preparation containing 25% insulin lispro and 75% insulin lispro protamine suspension. This pharmaceutical-grade insulin formulation represents a crucial research tool for investigating diabetes pathophysiology, glucose metabolism, and insulin receptor dynamics. Research scientists at Stroid UK Shop utilise this preparation to examine rapid-acting and intermediate-acting insulin profiles in controlled laboratory environments.
Research Applications and Mechanisms
The dual-action formulation enables comprehensive studies of both immediate and sustained insulin response patterns. The rapid-acting insulin lispro component demonstrates onset within 15 minutes in research models, while the protamine-suspended fraction provides extended activity profiles lasting up to 24 hours. Researchers investigate this preparation alongside other compounds from our insulin research category to examine glucose homeostasis mechanisms, receptor binding kinetics, and metabolic pathway modulation. Studies frequently examine the preparation’s effects on hepatic glucose production, peripheral glucose uptake, and adipocyte metabolism in various experimental models.
Technical Specifications and Storage
| Active Components | 25% insulin lispro, 75% insulin lispro protamine |
|---|---|
| Manufacturer | Eli Lilly and Company |
| Delivery Format | Pre-filled KwikPen injector (3ml) |
| Concentration | 100 units/ml (U-100) |
| Storage Temperature | 2-8°C refrigerated, protect from freezing |
| Stability | 28 days at room temperature once opened |
The preparation requires refrigerated storage and careful temperature monitoring throughout research protocols. Laboratory teams studying metabolic modulators often compare insulin preparations with compounds from our SARMS research collection and peptide research range to investigate anabolic signaling pathways and glucose metabolism interactions.
Research Compliance Statement
Humalog KwikPen Mix 25 is supplied exclusively for in-vitro laboratory research purposes and experimental protocols. This pharmaceutical preparation is not intended for human consumption, therapeutic use, or diagnostic applications. Research institutions must ensure proper handling protocols, waste disposal procedures, and regulatory compliance when investigating this insulin formulation in controlled laboratory environments.
